Ostrava
Ostrava
Ostrava, Czechia204 results · Page 1 of 9
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Exercise Snacks Enabled by an mHealth Intervention Delivered in General Practice to Promote a Sustainable Active Lifestyle in Adults With Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Not yet recruiting | Not applicable | 2026-10-09 | NCT07867665 | |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Active, not recruiting | Phase 3 | 2026-10-09 | NCT06641089 | |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Active, not recruiting | Phase 3 | 2026-10-09 | NCT06641076 | |
| A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity | Body Weight, Nutritional and Metabolic Diseases, Obesity, Abdominal, Overweight, Pathological Conditions, Signs and Symptoms, Prehypertension, Signs and Symptoms, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, prediabetes syndrome, vascular disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07794579 | |
| A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) | Chronic Disease, Disease Attributes, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bronchial disorder, bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, pulmonary emphysema, respiratory system disorder, respiratory tract infectious disorder | Recruiting | Phase 2 | 2026-10-08 | NCT07759245 | |
| Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arthritic joint disease, arthropathy, musculoskeletal system disorder, nutritional disorder, obesity disorder, osteoarthritis, overnutrition, rheumatic disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07353931 | |
| A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-10-08 | NCT07300969 | |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus | Recruiting | Phase 3 | 2026-10-08 | NCT07282600 | |
| A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, chronic renal failure syndrome, heart disorder, kidney disorder, kidney failure, nervous system disorder, stroke disorder, urinary system disorder, vascular disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07241390 | |
| Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung cancer, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-08 | NCT07222566 | |
| A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) | Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitus | Recruiting | Phase 3 | 2026-10-08 | NCT07222332 | |
| A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urinary Incontinence, Urinary Incontinence, Stress, Urination Disorders, Urogenital Diseases, Urological Manifestations, urinary system disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07202884 | |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-10-08 | NCT07165028 | |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | Arterial Occlusive Diseases, Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, nutritional disorder, obesity disorder, overnutrition, vascular disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07037433 | |
| A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | Hemic and Lymphatic Diseases, anemia, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Phase 3 | 2026-10-08 | NCT06499285 | |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Arterial Occlusive Diseases, Chronic Disease, Death, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, arteriosclerosis disorder, atherosclerosis, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, chronic renal failure syndrome, coronary artery disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, kidney disorder, kidney failure, metabolic disease, myocardial ischemia, nervous system disorder, peripheral arterial disease, peripheral vascular disease, type 2 diabetes mellitus, urinary system disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT06383390 | |
| A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT06292013 | |
| A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT06052267 | |
| Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight | Body Weight, Crohn disease, Digestive System Diseases, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-10-07 | NCT06937099 | |
| Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study | Body Weight, Digestive System Diseases, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, nutritional disorder, obesity disorder, overnutrition, ulcerative colitis | Recruiting | Phase 3 | 2026-10-07 | NCT06937086 | |
| Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-07 | NCT06890598 | |
| A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections | Gram Negative Infections | Recruiting | Phase 2 | 2026-10-07 | NCT06828848 | |
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, bronchial disorder, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-07 | NCT06119581 | |
| A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-10-07 | NCT05556512 | |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-10-07 | NCT05243797 |